Abstract

PURPOSE: The purpose of our study was to examine the effects of a commercially available amniotic suspension allograft (ASA) (ReNuTM, Organogenesis, Canton, MA) in a patient population with moderate osteoarthritis of the hip.METHODS: Ten patients with symptomatic hip osteoarthritis, defined as Tonnis grade 1 or 2 on radiographic examination, were prospectively enrolled. Each patient received a single image-guided injection of ASA into the hip joint. Patient-reported outcomes measures, including the iHOT12, mHHS, and SANE scores were recorded at baseline, 6 months, and 12 months post-injection. A linear regression model was performed to detect differences in outcome scores from baseline.RESULTS: Nine patients had complete 12-month data available for analysis. One patient failed treatment and underwent arthroplasty at 2 months post-injection. The cohort includes 5 males and 4 females, ages 47-67. iHOT scores demonstrated a significant improvement between baseline and 12 months (p = 0.02). SANE scores demonstrated a significant difference between baseline and 6 months (p < 0.01), as well as between baseline and 12 months (p < 0.01). mHHS scores demonstrated a significant difference between baseline and 6 months (p = 0.02) and between baseline and 12 months (p = 0.01). There were no major adverse events in the course of the study period.CONCLUSION: This study demonstrates promising results for relief of pain and improvement in patient-reported outcomes with intra-articular ASA in patients with moderate osteoarthritis of the hip for up to one year, though the exact mechanism of action remains unknown.

View details for DOI 10.1016/j.arthro.2021.04.034

View details for PubMedID 33940131